An international panel will discuss small nonpeptide GLP-1 receptor agonists and what this research means for the outlook of diabetes treatment. Julio Rosenstock, MD, will present data from ACHIEVE-1, a trial for the oral GLP-1 receptor agonist orforglipron.

Investigators, including John B. Buse, MD, PhD, will detail the key findings of a study to determine whether a new oral formulation of semaglutide is a safe and effective alternative to the injectable formulation.

Subodh Verma, MD, PhD, FRCSC, will share key results from a clinical trial using semaglutide in patients with type 2 diabetes and peripheral artery disease.

Among the panelists, Ania M. Jastreboff, MD, PhD, will discuss results for participants without type 2 diabetes, and Harold Bays, MD, will discuss results for participants with the disease.

Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.

PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.

Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.

Steven B. Heymsfield, MD, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.

Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.